Frederick W. Gluck
Net Worth
Last updated:
What is Frederick W. Gluck net worth?
The estimated net worth of Mr. Frederick W. Gluck is at least $2,571,695 as of 26 Mar 2018. He owns shares worth $543,313 as insider, has earned $1,523,382 from insider trading and has received compensation worth at least $505,000 in CytomX Therapeutics, Inc..
What is the salary of Frederick W. Gluck?
Mr. Frederick W. Gluck salary is $50,500 per year as Co-Founder & Independent Director in CytomX Therapeutics, Inc..
How old is Frederick W. Gluck?
Mr. Frederick W. Gluck is 90 years old, born in 1935.
What stocks does Frederick W. Gluck currently own?
As insider, Mr. Frederick W. Gluck owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | Co-Founder & Independent Director | 271,643 | $2 | $543,313 |
What does CytomX Therapeutics, Inc. do?
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Frederick W. Gluck insider trading
CytomX Therapeutics, Inc.
Mr. Frederick W. Gluck has made 8 insider trades between 2015-2018, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of CTMX stock worth $159,640 on 26 Mar 2018.
The largest trade he's ever made was exercising 93,124 units of CTMX stock on 9 Aug 2016. As of 26 Mar 2018 he still owns at least 271,643 units of CTMX stock.
CytomX Therapeutics key executives
CytomX Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Alison L. Hannah M.D. (64) Senior Vice President & Chief Medical Officer
- Dr. Amy C. Peterson M.D. (58) Executive Vice President & Chief Devel. Officer
- Dr. Sean A. McCarthy D.Phil., DPHIL (58) Chairman, Chief Executive Officer & Pres
- Mr. Carlos Campoy (60) Senior Vice President & Chief Financial Officer
- Mr. Frederick W. Gluck (90) Co-Founder & Independent Director
- Mr. Lloyd A. Rowland Jr., J.D. (68) Senior Vice President, Gen. Counsel, Chief Compliance Officer & Sec.